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To the Editor: In ‘Diagnosis and salvage of an immature
fistula’ by Bhimani and Asif,1 the interrelationship of several
issues—the importance of fistulas, the salvage of fistulas, and
the movement toward earlier initiation of dialysis—is
apparent.
In the case presentation, the patient began dialysis therapy
through a percutaneous catheter with a recent serum
creatinine level of 5.2 mg per 100 ml. Assuming reasonably
typical body weight, GFR (glomerular filtration rate) was
B10–15 ml min1. Therefore, the initiation of dialysis was
probably in the absence of overt uremic symptoms, in
accordance with the recent K/DOQI (Kidney Disease Out-
comes Quality Initiative) guidelines that stress earlier
initiation and GFR as an important metric—first specified
at 10.5 ml min1 2 and later revised to 15 ml min1.3
Unfortunately, the patient suffered complications of
percutaneous dialysis—sepsis and malfunction—requiring
several catheter replacements.
It is worth stressing that K/DOQI does not propose the
GFR metric as a mandate, and especially not as an urgent
mandate. Instead, it notes that ‘It is difficult to make a
recommendation for initiating renal replacement therapy
based solely on a specific level of GFR,’ and discusses the
difficulty, to date, that clinical studies have had in
demonstrating the benefit of early dialysis.3 Importantly,
three conditions have been listed that ‘may indicate that
dialysis is not yet necessary’ despite reaching the proposed
GFR, including stable body weight, acceptable nutritional
indices, and absence of symptoms.2
The case presentation suggests the need to specify a
fourth restraint to early initiation of dialysis: the absence
of acceptable access. The putative benefits of earlier dialysis
are certainly incremental; the purported risk of waiting
will accrue slowly over time, not all at the instant of
15 ml min1. The possible risk of deferring dialysis for a short
period while waiting for appropriate access must be weighed
against the frequent complications of percutaneous catheters.
In a risk vs benefit calculation, it might be concluded that
placing a catheter in the relatively asymptomatic patient to
begin ‘early’ dialysis is not warranted. Acceptable alternatives
include the salvage of an immature fistula, the placement
of a first or new fistula, ‘bridging’ peritoneal dialysis,
even placement of a graft. Many fistulas are usable after only
4–6 weeks; salvaged fistulas or peritoneal dialysis catheters
even sooner and newer graft material allows immediate
cannulation.
Taken a step further, if a fistula irreversibly throm-
boses shortly after dialysis initiation, it may be reasonable,
in some patients, to stop dialysis until a new appropriate
access is available, rather than to reflexively continue
dialysis, in all patients, through placement of a percutaneous
catheter.
One reason for the epidemic of catheter prevalence may be
the ‘too-early’ initiation of dialysis through catheters.
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We concur with Sheldon Hirsch.1 There should be a high
threshold for tunneled hemodialysis catheter insertion.
Such devices should only be placed when renal replace-
ment therapy is required.
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To the Editor: Agarwal et al.1 demonstrated that a single
dose of iron sucrose causes greater proteinuria than
ferric gluconate in a crossover trial of 12 patients with
stage 3–4 chronic kidney disease. The toxicity of iron prepa-
rations on renal tubular epithelial cells is becoming increas-
ingly recognized in experimental settings.2 Although not
addressed in the original design of the trial, using the
blood sampling obtained during the first and second phase
of the study, a complementary analytical approach would
be to examine whether the use of either parenteral iron
preparation was associated with a higher incidence of
transient elevation in serum creatinine, which would define
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acute kidney injury in the setting of preexisting chronic
kidney disease.
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We did not collect post-infusion serum creatinine, so we
are unable to comment on the occurrence of acute renal
failure. The time frame of the study is simply too short to
detect progression of renal injury. The benefits and risks of
iron use in nephrology need to be clarified further.
A larger, NIH-funded, randomized trial is under way to
examine the effects of iron administration in patients with
chronic kidney disease on GFR (glomerular filtration rate)
slopes.
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Gabapentin as a therapeutic
option in uremic pruritus
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To the Editor: We read with interest the ‘Renal consult’ on
uremic pruritus by Keithi-Reddy et al.,1 but we believe that a
major point regarding this topic has not been considered by
the authors. An emerging and intriguing pathogenetic
hypothesis on pruritus suggests that it can be due to
peripheral nerve fiber damage associated with a central
sensitization, leading to a diminished threshold of perception
of itch. This hypothesis is similar to that proposed for
neuropathic pain, in which nerve fiber damage and central
‘windup’ phenomenon are thought to be major patho-
mechanisms. Ongoing studies are now trying to clarify the
neurophysiologic pathways shared by itch and neuropathic
pain. Gabapentin, a medication widely used for a spectrum
of neuropathic pain syndromes, has recently been added
to the therapeutic armamentarium of uremic pruritus. Our
experience2 and other published randomized trials3,4 have
demonstrated that gabapentin can be effective and safe for
uremic pruritus, and that it also ameliorates neuropathic
symptoms (that is, restless leg syndrome, diabetic neuro-
pathy, and insomnia) that often affect hemodialysis patients’
quality of life. On the basis of these considerations, we believe
that Keithi-Reddy et al. should have discussed this point
and included gabapentin among the therapeutic options for
uremic itch.
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In response to our article,1 Manenti et al.2 suggest a role
for gabapentin in the management of uremic pruritus.
They make a similar point in a recent article.3 Gabapentin
is structurally related to c-amino butyric acid (GABA).
However, gabapentin does not bind to GABAA or GABAB
receptors, and does not appear to influence synthesis or
uptake of GABA. High-affinity gabapentin-binding sites
have been located throughout the brain and correspond to
the presence of presynaptically located voltage-gated
calcium channels. This channel appears to modulate the
release of excitatory neurotransmitters that participate in
epileptogenesis and pain sensation. Hence, gabapentin has
been used for the treatment of neuropathic pain. However,
its role in uremic pruritus is not well established. In a
randomized controlled crossover trial, Gunal et al.4
evaluated the effect of gabapentin (300 mg given thrice
weekly after dialysis) versus placebo in treating 25
hemodialysis patients for pruritus. Gabapentin lowered
the mean pruritus score (from 8.4 to 1.2 for gabapentin
versus 8.4 to 7.6 with placebo-treated patients). However,
this study had several limitations, including a small
sample size, limited information on demographics of the
study population, subjective evaluation of itching, only
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